Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SYRE with free AI briefings, catalyst countdowns, and dilution alerts.

SYRE · Spyre Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash, Pro Forma
61.1mo Cash Runway
Follow SYRE by email Get an email when SYRE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SYRE, unsubscribe in one click. Privacy

📣 What SYRE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SPY001 Ulcerative Colitis Phase 2 · NCT07012395 Recruiting
SPY002 Ulcerative Colitis Phase 2 · NCT07012395 Recruiting
SPY002-072 Rheumatoid Arthritis Phase 2 · NCT07148414 Active not recruiting
SPY003 Ulcerative Colitis Phase 2 · NCT07012395 Recruiting
SPY072 Hidradenitis Suppurativa (HS) Phase 2 · NCT07766005 Recruiting
SPY001-001 Healthy Phase 1 · NCT06448247 Completed
SPY002-091 Healthy Phase 1 · NCT06672718 Completed
SPY003-207 Healthy Phase 1 · NCT06873724 Active not recruiting

Also used in these trials (approved or third-party drugs, not SYRE's own candidates): Bimekizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SYRE had $1.1B in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $1.5B pro forma, before operating spending after that date:

It burns about $73.7M/quarter from operations, an estimated runway of 61.1 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SYRE files for a raise →

👥 Who Owns SYRE

Insiders 1.6% Other 5%+ holders 24.9% Institutions (409 holders) 73.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Harwin Peter Evan 5%+ holder (13D) 10,185,961 10.73% 2026-10-07
Peter Harwin 5%+ holder (13D) 9,016,702 9.49% 2026-04-16
Paradigm BioCapital Advisors LP 5%+ holder (13G) 4,457,450 4.69% 2026-09-24
Fairmount Funds Management LLC
Director · +354,071 options
Insider 812,076 0.86% 2026-06-23
Cameron Turtle
Chief Executive Officer, Director · +528,000 options
Insider 537,540 0.57% 2026-10-01
Scott L Burrows
Chief Financial Officer · +452,357 options
Insider 79,762 0.08% 2026-09-30
Michael Thomas Henderson
Director · +8,026 options
Insider 68,606 0.07% 2026-06-22
Jeffrey W. Albers
Director · +53,026 options
Insider 9,360 0.01% 2026-08-07
Heidy King-Jones
Chief Legal Officer and Corporate Secret · +622,478 options
Insider 2,845 0.00% 2026-10-01

Share count 94,969,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SYRE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SYRE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.